Samlyn Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Samlyn Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-81,000	Closed	-$3.87M	–	147
2016 Q4	$3.87M	Buy	+81,000	New	+$3.21M	0.09%	111

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Samlyn Capital's IONS Position: Q1 2017 in Review

Samlyn Capital sold out of Ionis Pharmaceuticals (IONS) in Q1 2017, closing a stake of 81,000 shares — an estimated $3.87M sold.

Samlyn Capital first reported a position in IONS in Q4 2016 and held it in 1 quarter. The position peaked at $3.87M in Q4 2016. 271 funds tracked by Wall St. Rank hold IONS as of Q1 2017.

Samlyn Capital reported no remaining Ionis Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Samlyn Capital sold 81,000 Ionis Pharmaceuticals shares in Q1 2017, an estimated $3.87M.
Samlyn Capital first reported a position in Ionis Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Samlyn Capital's Ionis Pharmaceuticals position peaked at $3.87M in Q4 2016.
271 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2017.

Based on Samlyn Capital's 13F filing for Q1 2017, filed 15 May 2017.